The combination of durvalumab and tremelimumab offered a modest response rate in unselected patients with heavily pretreated metastatic sarcoma, but higher rates were seen in specific subtypes, including angiosarcoma and alveolar soft-part sarcoma.
An intense dose-dense chemotherapy approach offers better survival vs standard therapy, extending to 10 years in breast cancer patients with extensive lymph nodes.
The first phase II study of cabozantinib in soft-tissue sarcoma yielded several responses, including several subtypes such as alveolar soft-part sarcoma and myxoid liposarcoma.
The combination of axitinib and pembrolizumab was reasonably well tolerated and showed promising activity in patients with various subtypes of soft-tissue sarcoma, with the benefit seen primarily in those with alveolar soft-part sarcoma, according to a new study.
The EZH2 inhibitor tazemetostat has shown good activity and is very well tolerated in an analysis of three trials of patients with the rare sarcoma subtype known as epithelioid sarcoma.
Isolated limb perfusion with high-dose melphalan and TNF-alpha has a high response rate and results in good survival outcomes in patients with locally advanced angiosarcoma, according to results of a new study.
Adding trastuzumab to anthracycline and taxane-based chemotherapy does not result in worsening of long-term cardiac outcomes in patients with node-positive, HER2-positive early breast cancer, according to a new study.
The immune checkpoint inhibitor pembrolizumab demonstrated antitumor activity in a small trial of patients with advanced cervical cancer. The agent had a similar toxicity profile to that seen in other malignancies.
Men with Medicaid are more likely to present with metastatic prostate cancer than men presenting with prostate cancer who have private insurance, according to a new study. There are racial disparities in terms of prostate cancer outcomes among those privately insured, but not among Medicaid recipients.
Achievement of event-free survival at 24 months is highly predictive of overall survival in patients with peripheral T-cell lymphomas, according to a new study.